Ikena Oncology Inc. and Inmagene Biopharmaceuticals have announced the successful completion of a $75 million private placement following their merger. The financing round included participation from a syndicate of existing and new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors including BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. This strategic funding supports the newly formed company, ImageneBio, Inc., as it continues to advance its clinical trials and expand its operations. Following the merger and financing, ImageneBio is set to begin trading on Nasdaq under the ticker symbol "IMA" on July 28, 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。